P128 is an anti-staphylococcal protein consisting of the Staphylococcus aureus phage-K-derived tail-associated muralytic enzyme (TAME) catalytic domain (Lys16) fused with the cell-wall-binding SH3b domain of lysostaphin. In order to understand the mechanism of action and emergence of resistance to P128, we isolated mutants of Staphylococcus spp., including meticillin-resistant Staphylococcus aureus (MRSA), resistant to P128. In addition to P128, the mutants also showed resistance to Lys16, the catalytic domain of P128. The mutants showed loss of fitness as shown by reduced rate of growth in vitro. One of the mutants tested was found to show reduced virulence in animal models of S. aureus septicaemia suggesting loss of fitness in vivo as well. Analysis of the antibiotic sensitivity pattern showed that the mutants derived from MRSA strains had become sensitive to meticillin and other b-lactams. Interestingly, the mutant cells were resistant to the lytic action of phage K, although the phage was able to adsorb to these cells. Sequencing of the femA gene of three P128-resistant mutants showed either a truncation or deletion in femA, suggesting that improper cross-bridge formation in S. aureus could be causing resistance to P128. Using glutathione S-transferase (GST) fusion peptides as substrates it was found that both P128 and Lys16 were capable of cleaving a pentaglycine sequence, suggesting that P128 might be killing S. aureus by cleaving the pentaglycine cross-bridge of peptidoglycan. Moreover, peptides corresponding to the reported cross-bridge of Staphylococcus haemolyticus (GGSGG, AGSGG), which were not cleaved by lysostaphin, were cleaved efficiently by P128. This was also reflected in high sensitivity of S. haemolyticus to P128. This showed that in spite of sharing a common mechanism of action with lysostaphin, P128 has unique properties, which allow it to act on certain lysostaphin-resistant Staphylococcus strains.
INTRODUCTION
Staphylococcus aureus causes a variety of communityacquired and hospital-acquired infections in humans.
Antibiotic resistance is quite common in this organism and emergence of hospital-and community-associated meticillin-resistant S. aureus (MRSA) has worsened the situation further (David & Daum, 2010) . Resistance has also been reported against the latest drugs used for treating S. aureus such as vancomycin, daptomycin and linezolid (Kelley et al., 2011; Gu et al., 2013) . Thus, a persistent effort is required to discover new therapies against this important human pathogen.
Peptidoglycan hydrolases or enzybiotics derived from bacteria or phages have been shown to possess potent antibacterial activities, especially against Gram-positive pathogens (Fenton et al., 2010 ; Rodríguez-Rubio et al., 2013a; Szweda et al., 2012) . Based on their ability to cleave specific bonds in the peptidoglycan, the murein hydrolases are classified as glycosidases, amidases or endopeptidases (Fenton et al., 2010; Szweda et al., 2012) . The disruption of peptidoglycan results in leakage of cytoplasmic contents leading to cell death (Simmonds et al., 1996) . Amongst the phage-derived enzybiotics, endolysins have received maximum attention and some of them have been shown to be efficacious in animal models of bacterial infections (Schmelcher et al. 2012; Gilmer et al., 2013) . Another category of murein hydrolases possessing potent antibacterial activity is the bacteriophage tail-associated muralytic enzymes (TAMEs) (Paul et al., 2011) . In the phage life cycle, TAMEs are involved in puncturing the bacterial cell wall for facilitation of phage DNA injection into the bacterial cytoplasm (Nakagawa et al., 1985) . Since the TAME substrate (peptidoglycan) is conserved in a bacterial species, these enzymes have a broader spectrum of antibacterial activity compared to the narrower host range of bacteriophages (Paul et al., 2011; Narasimhaiah et al., 2013) . Attempts to isolate bacterial mutants resistant to the bactericidal action of muralytic endolysins have been unsuccessful (Loeffler et al., 2001; Schuch et al., 2002; Gilmer et al., 2013; Rodríguez-Rubio et al., 2013b) . This has been attributed to the essential nature of the targets of endolysins and the inability of bacteria to tolerate any changes in these structures. By contrast, S. aureus mutants resistant to lysostaphin, a muralytic endopeptidase acting on the pentaglycine cross-bridge, could be isolated at high frequency (Climo et al., 2001) . The mutations were mapped to the femA gene, which codes for pentaglycine synthase involved in addition of the second and third glycine of the pentaglycine bridge in S. aureus peptidoglycan. S. aureus strains carrying mutant copies of femA were shown to possess a single glycine residue in place of pentaglycine in the cell-wall cross-bridge (de Jonge et al., 1993; Stranden et al., 1997) . A number of Staphylococcus species are known to be naturally resistant to lysostaphin because of the presence of Fem-like proteins, which incorporate serine in place of a glycine in the pentaglycine cross-bridge of the peptidoglycan (DeHart et al., 1995; Sugai et al., 1997; Ehlert et al., 2000) . In a study involving FRET (fluorescence resonance energy transfer) assays, replacing the third glycine of a GGGGG sequence with a serine was shown to abolish the activity of lysostaphin on the FRET substrate (Bardelang et al., 2009) . Apart from those in fem genes, mutations in other genes have also been reported to confer resistance to lysostaphin. By screening a transposon mutant library of S. aureus for increased resistance to lysostaphin, Gründling et al. (2006) found mutations in the purine biosynthesis pathway and lyrA gene, which codes for an uncharacterized membrane protein.
P128 is a chimeric protein consisting of the catalytic CHAP domain of phage K ORF56 fused to the cell-wall-binding SH3b domain of lysostaphin (Paul et al., 2011) . The CHAP domain of P128 (Lys16) by itself has bactericidal properties, which is accentuated by its fusion to the SH3b domain (Paul et al., 2011) . P128 is potent killer of Staphylococcus species but had no inhibitory activity on a number of other Grampositive and Gram-negative bacteria tested (Vipra et al., 2012) . Its unique property to specifically kill Staphylococcus species including MRSA strains and lack of cytotoxicity on eukaryotic cells (George et al., 2012) suggests that P128 has the potential for treating a variety of infections caused by drug-resistant strains of staphylococci. P128 is currently undergoing safety and efficacy trials in Singapore for its use as a topical agent for decolonizing nasal carriage of S. aureus, including MRSA (ClinicalTrials.gov identifier: NCT01746654).
In this study we show that mutants of MRSA resistant to P128 have fitness defects and become sensitive to meticillin and other b-lactams. The mutations conferring resistance to P128 were mapped to the femA gene linking the mechanism of action of P128 to the pentaglycine crossbridge in S. aureus peptidoglycan. In addition to the GGGGG pentapeptide, P128 was shown to have cleaving activity on GGSGG and AGSGG, which are known to form cross-bridges in Staphylococcus haemolyticus, a coagulasenegative Staphylococcus (CoNS) species causing nosocomial infections (Natoli et al., 2009) .
METHODS
Plasmids, strains and culture conditions. The plasmids and strains used in this study are listed in Table 1 . S. aureus cultures were routinely grown in trypticase soy broth (TSB) or TS agar (Hi-Media), and LB broth or agar (Hi-Media) at 37 uC.
Generation of mutants resistant to P128. A diverse set of 50 Staphylococcus strains including clinical isolates of MRSA, human nasal commensals and strains isolated from canine pyoderma were selected for isolation of mutants resistant to P128. The cultures were grown in sub-MIC (0.56) concentrations of P128 and plated on MH agar containing 100 or 200 mg P128 ml 21 , incubated at 37 uC and observed for the appearance of colonies for up to 72 h. Only four strains (BK1, BK22, BK30 and CPD70) showed colonies growing on P128-containing plates, which were taken up for characterization. The lack of colonies on P128 plates inoculated with other strains was not investigated further.
Stability of mutant strains. The stability of P128-resistant mutant phenotypes was followed by repeated subcultures in LB broth without P128 for up to 14 days. The cultures were tested for P128-resistance/ sensitivity on day 5 and day 14 by lawn inhibition, c.f.u. drop and MIC assays.
In vitro growth kinetics. In vitro growth kinetics of P128-resistant mutants and the corresponding parent strains grown on LB agar and TS agar were performed in TSB or LB broth in triplicate. The cultures were suspended in TSB or LB broth to achieve an OD 600 54.0. From this suspension, 0.5 ml was inoculated into 50 ml pre-warmed TSB or LB broth in a 250 ml conical flask. The cultures were incubated with shaking at 200 r.p.m. at 37 uC. The OD 600 was determined at various time intervals during the incubation period. The experiment was performed in triplicate and repeated twice.
Spa typing. Spa typing of various S. aureus strains was performed according to the procedure described by Shopsin et al. (1999) . Amplified PCR products were visualized in ethidium-bromide-stained gel and the DNA fragment was subjected to sequencing. The DNA sequence was compared with the sequences of known spa types using the Ridom database (http://spa.ridom.de/spatypes.shtml.).
Binding of phage K to P128 mutants. Adsorption of Phage K to S. aureus RN4220, BK1, BK30, BK1R and BK30R was studied. The cultures were harvested from agar plates using LB broth and the OD 600 was adjusted to 1.0. The cultures were infected with phage K at an m.o.i. of 0.1, incubated at 37 uC for 20 min and centrifuged at 9200 g for 5 min. The supernatant was filtered through a 0.2 mm filter and serially diluted supernatant fractions were spotted on a S. aureus RN4220 lawn. The plates incubated overnight were observed for clearance of the bacterial lawn in areas of spotting. Escherichia coli C was taken as a negative control for phage K adsorption. The assay was performed in duplicate and repeated three times.
In vivo phenotype in mice. Animal experiments were approved by the Institutional Animal Ethics Committee and the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). GangaGen is registered with CPCSEA (registration no. 1193/c/08/CPCSEA dated 21/4/2008). In all the experiments, five 8-to 9-week-old, healthy, female BALB/c mice were used in each group. For preparing inocula, BK30 or BK30R cultures were grown overnight on nutrient agar containing 5 % sheep blood. Colonies were harvested by flooding the plate with sterile 0.85 % NaCl. The harvested cells were pelleted by centrifugation (5800 g, 10 min) and resuspended in sterile 0.85 % NaCl to obtain 1610 7 -4610 7 c.f.u. ml 21 . BK30 or BK30R (200 ml) was injected into mice intaperitoneally. Mice were observed for morbidity and mortality for up to 48 h. Three animals were chosen randomly from each group and spleens and kidneys were collected for estimating the organ load.
Statistical analysis. The differences in c.f.u. obtained in in vitro kill assays were analysed by Student's t-test. A value of P,0.05 was considered significant. The statistical significance of c.f.u. obtained from spleen and kidney of animals was evaluated by one-way analysis of variance (ANOVA) followed by the Tukey-Kramer multiple comparisons test. A value of P,0.01 was considered to be significant. For comparison of mortality in animals infected with BK30 or BK30R, a Kaplan-Meier survival plot was drawn and the log rank test was performed using MedCalc (version 12.1.4.0). A value of P,0.05 was considered to be significant. Statistical analysis was done using Microsoft Excel and GraphPad InStat trial version from GraphPad Software.
Genomic DNA isolation. Genomic DNA of various S. aureus strains was isolated using a bacterial genomic DNA extraction kit (Sigma Aldrich) by a procedure suggested by the manufacturer with some modifications. Briefly, overnight cultures were centrifuged and the pellet was resuspended in 200 ml Gram-positive lysis solution provided in the kit. Glass beads (Sigma Aldrich) were added to the cell suspension and the contents were vortexed for 3 min. Lysostaphin (20 mg ml
21
) was then added and the mixture was incubated at 37 uC for 30 min. Lysis solution C was added followed by proteinase K (40 mg ml 21 ) and the tubes were incubated at 55 uC for 10 min. DNA was precipitated by adding 200 ml 100 % ethanol and loaded onto a pre-equilibrated column for further purification according to manufacturer's instructions.
Glutathione S-transferase (GST) fusion constructs. For fusing the desired peptide sequence to the C terminus of GST and N terminus of staphylokinase (SAK), the peptide-coding sequence was incorporated into the forward primer used for amplification of the SAK coding region. The SAK coding region was purified from S. aureus ATCC 8325 genomic DNA. The sequences of primers used are provided in Table S1 (available in the online Supplementary Material). PCR conditions were as follows: denaturation at 95 uC for 5 min followed by 30 cycles of amplification at 95 uC, 50 uC and 72 uC for 30 s each and finally extension at 72 uC for 10 min. The PCR-amplified pentaglycine-SAK fusion coding fragments were cloned into the EcoRI site of pGEX 4T-1 to obtain pGDC279, pDGC281 and pGDC294. For generating GGSGG, AGSGG and GSSGG fusions, site-directed mutagenesis was performed as described below. The sequences of the mutagenic primers are given in Table S1 .
Site-directed mutagenesis. Site-directed mutatagenesis was performed using a QuikChange site-directed mutagenesis kit (Stratagene). PCR conditions consisted of initial denaturation for 30 s at 95 uC followed by 18 cycles of 95 uC for 30 s, 55ufor 1 min and 68 uC for 6 min, and final extension at 68 uC for 5 min. A 10 ml aliquot of the DpnI-digested reaction mix was used to transform E. coli Top10 cells. The desired mutation in the clone was confirmed by DNA sequencing. GST-GGGGG-SAK fusion in pGEX-4T This study pGDC281
GST-GAAAG-SAK fusion in pGEX-4T This study pGDC294
GST-GGG-SAK fusion in pGEX-4T This study pGDC293
GST-GGSGG-SAK fusion in pGEX-4T This study pGDC397
GST-AGSGG-SAK fusion in pGEX-4T This study pGDC399
GST-GSSGG-SAK fusion in pGEX-4T This study P128 acts on S. aureus pentaglycine cross-bridge Protein purification. P128 and Lys16 were purified as described previously (Paul et al., 2011) . N-terminal His-tagged lysostaphin was expressed in soluble form in E. coli ER2566 and purified through Ni
2+
-NTA affinity matrix (Qiagen), as described previously (Saravanan et al., 2013) . For GST fusion proteins, induced cell pellets were resuspended in 2 ml 10 mM Tris buffer (pH 8.0) and were lysed by sonication. The lysed cells were centrifuged at 13 000 r.p.m. for 10 min and the supernatant was taken for purification. The glutathione Sepharose 4 fastflow matrix column was equilibrated with 50 mM Tris/HCl buffer (pH 8.0) containing 1 % Triton X-100 and 150 mM NaCl. After washing, the bound GST fusion proteins were eluted using 10 mM reduced glutathione in 50 mM Tris/HCl, (pH 8.0) and dialysed against 50 mM Tris/HCl buffer (pH 8.0). All the proteins used in the study were purified to approximately .90 % level. Protein estimation was performed by Bradford's dye-binding method (Bradford, 1976) .
In vitro cleavage of GST fusion peptides. For monitoring cleavage of fusion peptides, 20 mg purified GST fusion peptides were individually incubated with 10 mg purified P128, Lys16 (Paul et al., 2011) or lysostaphin in the presence of 50 mM Tris/HCl (pH 8.0) at 37 uC for 16 h. The samples were analysed by 15 % SDS-PAGE. The N-terminal sequence of the cleaved SAK fragment was determined by the sequencing facility at the Biochemistry Department of the Indian Institute of Science, Bangalore, India.
MIC, lawn inhibition spot assay and c.f.u. drop assay. MIC was determined using a modified Clinical and Laboratory Standards Institute (CLSI) broth microdilution procedure described previously (Vipra et al., 2012) . For lawn inhibition spot assay, freshly grown culture was spread on a LB agar plate and allowed to dry. Various amounts of protein were spotted on the dried plate and incubated overnight at 37 uC. Inhibition of bacterial growth resulted in a zone of clearance. The c.f.u. drop assay was performed as described previously (Paul et al., 2011) . Briefly, 2 mg P128 was allowed to act on 10 7 c.f.u. of S. aureus in 200 ml saline for 1 h at 37 uC with shaking at 200 r.p.m. The reaction volume was then increased to 1 ml with LB and various dilutions were plated on LB agar plates to determine the residual bacterial counts. The c.f.u. drop assays were done in duplicate and repeated three times.
RESULTS

Characterization of P128-resistant mutants
Following the procedure described in Methods, colonies were observed in P128-containing plates inoculated with the three MRSA strains (BK1, BK22, BK30) and one Staphylococcus equorum strain from canine pyoderma (CPD70) ( Table 1) . Based on this, the frequency of resistance development was calculated to be approximately 3.5610 26 to 2610 -7 . The induced frequency of resistance against lysostaphin has been reported to range from very high to low (5.3610 21 to 1.0610
27
) (Climo et al., 2001) . One putative resistant colony from each strain was taken up for further characterization. The colonies showed confluent growth when plated on 200 mg ml 21 P128-containing MH agar plates (Fig. 1a) and the MICs on the mutants were found to be .2 mg ml 21 (Table 2) . Four putative mutants, designated BK1R, BK22R, BK30R and CPD70R, were checked for susceptibility to P128 by lawn inhibition assay and c.f.u. reduction assay. By spotting 10 mg P128 on parent Staphylococcus cultures clear zones of lysis were seen, whereas there was no such clear zone in the case of mutant cultures (Fig. 1a) . In the c.f.u. drop assay, the parent strains and the sensitive control Staphylococcus carnosus showed a 3-6 log reduction in c.f.u. upon treatment with P128 (10 mg ml
21
) for 1 h. (Fig. 1b) . No significant reduction in c.f.u. was obtained in any of the resistant mutants under similar conditions. This suggested that the mutants could resist the bactericidal action of P128. In order to make sure that the resistance to P128 was mediated through the catalytic domain of P128, susceptibilities of the mutants to Lys16 were assessed by lawn inhibition assay. As seen in Fig.  1(c) , 0.5 mg P128 or 2.5 mg Lys16 created zones of clearance upon spotting on cultures of BK1 and BK30. However, even 20 mg of either of these proteins did not produce any zones of clearance on BK1R or BK30R. Thus, it could be concluded that strains BK1R and BK30R were resistant to the action of the catalytic domain of P128. In order to make sure that the resistant mutants were derived from their respective parents and to rule out any cross-contamination issues, the strains were subjected to spa typing by the procedure described in Methods. As seen in Table 2 , the parent and mutant strains belonged to the same spa type, which confirmed that they were isogenic.
Two unstable mutants reverted back to the parental phenotype
In order to determine the stability of the resistance phenotype the mutant strains were grown in the absence of P128 for 14 days with regular subculturing and were monitored for P128 sensitivity by MIC, lawn inhibition and c.f.u. drop assay. It was observed that the mutant strains formed smaller colonies on LB agar plates compared with the parent strains (Fig. S1 ). Upon subculture, it was seen that BK1 and BK30 mutants were stable and had retained the small colony morphology and were resistant to P128 until 14 days (Fig. S1a) . Interestingly, CPD70R showed signs of reversion in the second passage and was fully reverted to P128-sensitivity after the fifth passage (Fig. S1a , Table S2 ). The reverted culture showed normal growth and had normal-sized colonies on agar plates (Fig. S1) . Similarly, BK22R also reverted to the parent phenotype of large colony and P128-sensitivity, although it took nine subcultures to do so. The susceptibilities of the reverted BK22R and CPD70R cultures to P128 as measured by c.f.u. reduction assays were similar to those of their parent strains (Fig. S1b, Table S2 ) confirming that they had lost the P128-resistance phenotype. This clearly demonstrated that some of the P128-resistant mutants were unstable and could revert back to the wild-type phenotype upon subculture in the absence of P128.
P128-resistant mutants lose MRSA phenotype and are hypersensitive to b-lactams Since P128 acts on the cell wall, to understand whether the resistance mutation brings any alterations in the susceptibility to cell-wall inhibitors, the MIC of oxacillin was tested against the P128-resistant mutants. As seen in Table  2 , the MIC of mutant derivatives of all the three MRSA strains, BK1, BK22 and BK30, dropped drastically from .256 mg ml 21 to ,0.1 mg ml 21 . The mutant strains were also found to be highly sensitive to meticillin as demonstrated by E-test in agar plates (Fig. S2) Thus, all the mutants were converted from MRSA to meticillin-sensitive S. aureus (MSSA). MIC measurements of other b-lactams, cefalotin, ceftizoxime, carbenicillin, ceftriaxone, cefalexin, amoxicillin, cefazolin and oxacillin, showed that the mutant strains were sensitive to these compounds as well (data not shown). The sensitivity of the BK1R and BK30R mutant strains to a number of non-b-lactam antibiotics (kanamycin, streptomycin, clindamycin, vancomycin, mupirocin and moxifloxacin) remained unchanged (Table S3 ), suggesting that the mutation had only affected the cell-wall physiology of the bacteria in a specific way. Reduction in MIC of oxacillin and other b-lactams to sensitive levels indicated that the mutations in these strains might have altered proteins involved in peptidoglycan metabolism.
P128-resistant mutants show reduced rates of growth in vitro
Observations of colonies on LB and TS agar plates indicated that all four mutant strains, BK1R, BK30R, BK22R and P128 acts on S. aureus pentaglycine cross-bridge CPD70R, formed smaller colonies, probably because of their reduced growth rates. Growth kinetics of BK1, BK30 and their stable mutant derivatives in liquid cultures showed that BK1R and BK30R had significantly slower growth rates compared with the corresponding parent strains (Fig. S3) . Additionally, the rate of growth of BK1R was much slower than that of BK30R in both LB and TS media. However, upon prolonged incubation up to 48 h, the colony size on plates and the OD 600 values in liquid cultures of the mutants and the parental stains were similar.
Peptidoglycan from resistant cells is refractory to the action of P128
Since bacteriophage CHAP domain proteins possess muralytic activity and are able to cleave a variety of bonds in bacterial peptidoglycan (Becker et al., 2009; Fenton et al., 2010; Szweda et al., 2012; Gilmer et al., 2013) , resistance to P128 might involve changes in peptidoglycan. To find out whether the resistant mutants had alterations in peptidoglycan, which would affect their cleavage by P128, enzymic activity of P128 on peptidoglycan of wild-type and corresponding mutants was studied by zymogram using the protocol described by Lepeuple et al. (1998) . Since the sensitivity of this assay is very high, the amount of proteins used was quite low compared to the MIC values determined on the strains. As seen in Fig. 2 , P128 was able to cleave peptidoglycan of BK1 and BK30 parent strains very efficiently as a zone of clearing could be seen with as little as 25 ng P128. The peptidoglycans of the mutant strains (BK1R and BK30R), however, were found be poor substrates for P128 as a faint zone of clearing could be seen only with concentrations higher than 250 ng P128. Similarly, both BK1R and BK30R were resistant to the action of Lys16 (Fig. 2) , the enzymic domain of P128. This demonstrated that the mutations had caused alterations in the peptidoglycan of staphylococci, making them resistant to the enzymic action of P128.
P128 mutants are resistant to phage K lysis although they can adsorb phage
Since P128 possesses the catalytic domain (Lys16) derived from S. aureus phage K, we tested the susceptibility of P128-resistant mutants to phage K. As seen in Fig. 3(a) , both BK1 and BK30 parent strains were sensitive to the action of phage K and abundant plaques were visible in 10 26 diluted phage preparations. By contrast, neither BK1R nor BK30R showed plaque formation under similar conditions. This clearly demonstrated that the P128-resistant strains had become refractory to the action of phage K as well. We decided to find out whether the resistance was because of inability of the phage to bind to the bacterial cells or if they could bind but could not replicate. As shown in Fig. 3(b, c) , E. coli C used as a negative control did not show any significant binding to phage K as the phage titre seen on the Zymogram analysis of BK1 and BK30 parent and resistant variants using P128 and Lys16. Cell walls prepared from the respective strains were run on a SDS-PAGE gel and processed as described in Methods. P128 (25-500 ng) or Lys16 (0.60-20 mg) was used for assessing the enzymic activity on peptidoglycans of sensitive or resistant variants. All the zymograms were repeated at least three times. ) obtained with mutant strains showed that both BK1R and BK30R were able to bind to the phage almost as efficiently as the parent strains. This demonstrated that although phage K could bind to BK1R and BK30R, cell lysis did not take place, probably due to inability of phage K to cleave the altered peptidoglycan for injecting DNA to initiate replication.
P128-resistant mutants show reduced virulence
In order to assess any changes in the virulence of P128-resistant mutants, one of the stable mutants, BK30R, was compared with its parent strain for its ability to survive in mouse organs and to kill animals. Initial virulence studies conducted with the BK30 parent strain showed that 10 9 c.f.u. was required for killing .50 % of the animals. In two independent experiments, BK30R was found to be attenuated in virulence as no mouse inoculated with this strain succumbed to infection (Fig. S4) . By contrast, the BK30 parent strain caused significant mortality (60 %) in mice, which was statistically significant (P,0.05). As shown in Table S4 and a scatter plot in Fig S5, the total c.f.u. obtained from the spleen of mice infected with BK30R was significantly less than that found in the spleen of mice infected with BK30. A similar c.f.u. difference between BK30R and BK30 was observed in kidneys. The c.f.u. difference observed in the spleen and kidney of mice infected with BK30 and BK30R was found to be statistically significant (P,0.01). These experiments suggested that the mutation had affected the ability of bacteria to survive in animals and had reduced their ability to cause mortality. Thus, there was a loss of fitness in P128 mutants in their ability to survive in vitro and in vivo.
Genetic characterization of P128-resistant mutants
The phenotypic characterization of P128-resistant mutants of S. aureus had shown loss of fitness in vitro and in vivo accompanied by conversion of the MRSA phenotype to MSSA. As these mutants also showed cross-resistance to lysostaphin, the mechanism of P128 resistance was expected to have a common element with lysostaphin resistance. Since the mechanism of lysostaphin resistance involves changes in the femA gene (de Jonge et al., 1993; Kusuma et al., 2007) , we decided to analyse the femA genes of strains BK1R, BK22R and BK30R by PCR using primers shown in Fig. S6a . The full-length femA gene is reported to be 1302 bp, coding for a protein of 433 aa residues. By PCR, all the parent strains (BK1, BK22 and BK30) that were MRSA and susceptible to P128 showed the presence of an intact femA gene ( Fig. S6b) with DNA sequence matching the reported sequence in the database. By contrast, in BK1R (MSSA and resistant to P128), a premature stop codon was observed in the femA gene at bp 900, which resulted in termination of the FemA polypeptide by 133 residues (Fig. S6b, c) . Similarly, in BK22R, a stop codon at bp 459 truncated the polypeptide by 280 residues. In BK30R, a PCR product of only~350 bp was observed, indicating that a part of the gene was deleted (Fig. S6b, lane 5) . DNA sequencing showed a deletion of femA starting from bp 327 and extending into the initiation codon (ATG) of femB, resulting in deletion of 325 aa in the FemA protein and abrogating formation of FemB. DNA sequence analysis of the femA gene of P128-resistant mutants suggested that, similar to lysostaphin, mutations in the femA gene were causing resistance to P128. Interestingly, the reversion of P128-resistant BK22R to the P128-sensitive parent phenotype could be explained by conversion of a premature stop codon, TAA to CAA (coding for Gln), leading to restoration of expression of the full-length FemA protein. The femA mutations in BK1R, BK22R and BK30R could result in formation of monoglycine cross-bridges instead of the usual pentaglycine bridges seen in wild-type strains of S. aureus (de Jonge et al., 1993; Stranden et al., 1997) . These observations led us to investigate whether the mechanism of action of P128 could involve cleavage of the pentaglycine cross-bridge of S. aureus.
Cleavage of pentaglycine (GGGGG) and other sequence in vitro: differences between substrate specificities of P128 and lysostaphin
Mapping of P128-resistance mutations in BK1R, BK22R and BK30R to femA genes suggested that the target of P128 could be the pentaglycine cross-bridge of the S. aureus cell wall. In order to confirm this, we investigated the cleavage of pentaglycine in vitro using GST fusion peptides (Fig. 4a) . For this purpose, a chimera of pentaglycine (GGGGG) and SAK was fused to the C terminus of GST (Fig. 4b) in the pGEX4T-1 vector, as described in Methods. The 16 kDa SAK protein, which is known to be expressed in soluble form in E. coli (Prasad et al., 2010) , served the purpose of a reporter in this assay. Upon cleavage of the pentaglycine linker, the SAK fragment was expected to become separated from the GST fusion (Fig. 4b) and would thus be seen as a new protein band on a SDS-PAGE gel. As shown in Fig.  4(c) , both lysostaphin and P128 were able to release SAK from the GST-GGGGG-SAK fusion protein with similar efficiency. In order to make sure that the cleavage was not because of the presence of the lysostaphin SH3b domain in P128, we tested the cleavage of the fusion protein using Lys16, the catalytic domain of P128. It was seen that Lys16 could cleave the fusion protein on its own, thus ruling out the role of SH3b in pentaglycine cleavage. Additionally, the SH3b domain alone did not show any activity on GST-GGGGG-SAK (Fig. S7 ). This finding is consistent with bactericidal activity shown by Lys16 alone (Paul et al., 2011) . N-terminal sequencing of the SAK fragment released upon cleavage showed that P128 was cleaving between the fourth and fifth Gly residues of pentaglycine (Fig. S8) . However, the ability of P128 to cleave at multiple sites in the cross-bridge as reported for lysostaphin (Warfield et al., 2006 ) cannot be ruled out at this stage.
Since there is no homology between lysostaphin and the P128 CHAP domain, we surmised that, in spite of acting on the same substrate, there could be differences in their mechanism of action. In order to see if the two proteins had differential preferences for substrates, we designed the following glycine-containing polypeptides as GST fusions: GST-GAAAG-SAK, GST-GSSGG-SAK, GST-GGG-SAK, GST-GGSGG-SAK and GST-AGSGG-SAK. The lysostaphin-producing strain of Staphylococcus (Staphylococcus simulans biovar staphylolyticus), which is known to be resistant to the action of lysostaphin by virtue of the presence of a lysostaphin immunity factor (Lif) (Heath et al., 1989) carries GGSGG cross-bridges in the peptidoglycan (Thumm & Götz, 1997) , Similarly, S. haemolyticus, an emerging pathogen in nosocomial infections is known to carry GGSGG and AGSGG cross-bridges in its peptidoglycan (Billot-Klein et al., 1996) .
It was seen that both P128 and lysostaphin did not cleave GST-GAAAG-SAK or GST-GSSGG-SAK fusions (Fig. 4d,  right panel, e) . Similarly, GST-GGG-SAK was found to be a poor substrate for both lysostaphin and P128, although P128 showed slightly better activity as seen by release of and sizes of the two domains of the fusion protein linked by GGGGG, GGSGG, GGG, AGSGG, GSSGG or GAAAG. (c) . Cleavage of the fusion proteins by P128, lysostaphin or Lys16 analysed by SDS-PAGE. The cleavage reaction was performed by the procedure described in Methods and the reaction products were loaded on a SDS-PAGE gel. P128, lysostaphin and Lys16 incubated in the absence of GST fusion proteins are shown on the left side of the panel. The middle and right side of the panel show the reaction products obtained after incubating GST-GGGG-SAK or GST-GGSGG-SAK fusion proteins with P128, lysostaphin or Lys16 proteins. (d) In vitro cleavage of GGG (left panel) and GAAAG (right panel) fusion peptides. (e) In vitro cleavage of AGSGG and GSSGG fusion peptides by P128 and lysostaphin. Lys16 is the catalytic domain of P128. The assay was repeated three times and results from one of the experiments are shown. Lyso, lysostaphin; MW, molecular size marker.
the SAK fragment (Fig. 4d, left panel) . Interestingly, GST-GGSGG-SAK, on which lysostaphin did not show any activity, could be cleaved by both P128 and Lys16 (Fig. 4c) . The substrate specificities of P128 and Lys16 were again found to be the same, demonstrating that the cleavage specificity of P128 was because of its catalytic CHAP domain and SH3b did not contribute towards this specificity. Another sequence from S. haemolyticus peptidoglycan, AGSGG, was cleaved by P128 but not by lysostaphin (Fig. 4e) . This set of data proved that although both lysostaphin and P128 act on pentaglycine, there are significant differences in their substrate specificities.
In vivo relevance of GGSGG and AGSGG cleavage: P128 can kill S. haemolyticus
In order to understand the physiological significance of differences in substrate specificities of P128 and lysostaphin we investigated the killing of staphylococci harbouring cross-bridge sequences other than GGGGG. In a spot assay on S. haemolyticus, 2, 5 and 10 mg P128 showed clear zones of lysis whereas lysostaphin failed to show any effect under these conditions (Fig. 5a ). In a cell-killing assay using P128 or lysostaphin at 50 mg ml
21
, P128 reduced the c.f.u. counts of S. haemolyticus by 6 logs, demonstrating a potent bactericidal activity on this species. No bactericidal effect was seen in lysostaphin treated cells (Fig. 5b) . This is consistent with the killing of S. simulans by P128 shown previously (Saravanan et al., 2013) . The potent activity of P128 on S. haemolyticus and S. simulans corroborates the biochemical finding of this study that, unlike lysostaphin, P128 is capable of cleaving a GGSGG-and AGSGGcontaining cross-bridge in the Staphylococcus cell wall.
DISCUSSION
Amongst the phage-or bacteria-derived murein hydrolases or enzybiotics, mechanism of resistance has been studied in detail only in the case of lysostaphin (Climo et al., 2001; Kusuma et al., 2007) . Attempts to isolate resistant mutants have been unsuccessful with other hydrolases including phage endolysins, which probably means that any changes in their substrates are lethal to the cell (Loeffler et al., 2001; Schuch et al., 2002; Gilmer et al., 2013; Rodríguez-Rubio et al., 2013a ). In the current study, the frequency of induced resistance against P128 was found to be comparable to the lower range value (1.0610
27
) reported for lysostaphin (Climo et al., 2001) . The reason for the unusually high frequency of lysostaphin resistant mutants (5.3610
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) observed in the earlier study is not known. The loss of susceptibility of P128-resistant mutants to Lys16, the catalytic domain of P128, proved that the mutants had become refractory to the enzymic activity of P128. The slow growth rates of mutants resistant to P128 in vitro and reduced virulence in an animal model pointed towards loss of fitness in vitro and in vivo. The loss of fitness in vitro and/ or in vivo amongst antibiotic-resistant bacteria was reported by Andersson & Hughes (2010) . Instability of some of the P128-resistant mutants as indicated by reversion to the parent phenotype suggests that the resistance imposes burden on their fitness, which drives the mutant bacteria towards loss of resistance phenotype. The loss of fitness shown by the stable P128-resistant mutants in vitro and in vivo suggests that these mutants are likely to be at a disadvantage for survival and spreading in a community. The reduction in virulence indicates that the mutant strains might be less pathogenic in humans as well. Similar loss of fitness shown by lysostaphin-resistant mutants (Kusuma et al., 2007) indicates that P128 and lysostaphin might share a common mechanism of resistance. The ability of the mutant cells to bind to phage K shows that the phage receptors on the cell surface are intact. The resistance of these mutants to phage K lysis can possibly be attributed to the inability of phage K to cleave the peptidoglycan for injecting DNA into the cell. The reduction in cleavage efficiency by P128 of peptidoglycan purified from resistant mutants, as shown by zymogram analysis, suggested that increased resistance of the mutants to P128 resulted from changes in the substrate of P128. Thus, presence of a common SH3b cell-wall-binding domain in lysostaphin and P128 cannot be the sole reason for cross-resistance of P128 mutants to lysostaphin.
The prokaryotic CHAP-domain proteins constitute a family of murein hydrolases of bacterial and phage origin characterized by active site Cys and His residues (Zou & Hou, 2010) . The mechanism of action of CHAP domains at the level of cellular killing of bacteria is not understood since there are no reports on isolation of mutants of bacteria resistant to the action of CHAP-domain proteins. Despite lack of any sequence or structural similarity of CHAP domains to lysostaphin (Rossi et al., 2009; Paul et al. 2011) , the P128-resistant S. aureus mutants were found to be resistant to lysostaphin. Earlier studies on lysostaphin-resistant mutants involving changes in femA genes (Stranden et al., 1997; Kusuma et al., 2007) have proven that lack of FemA activity in the cell can lead to reduction in growth rates and conversion of the MRSA phenotype to MSSA. Thus, it was not surprising that the femA genes were found to be mutated in P128-resistant mutants. It is worth mentioning that in an earlier study, screening a library of transposon mutants had led to recognition of femA mutations being responsible for reduction of S. aureus virulence in a mouse model of infection (Mei et al., 1997) . The reduced rates of growth in vitro, resistance to lysostaphin, conversion of MRSA to MSSA and attenuation of virulence in mice of P128-resistant mutants are consistent with the phenotypes of femA mutants reported previously (Mei et al., 1997; Kusuma et al., 2007) . The similarity of phenotypes shown by P128-resistant mutants and femA mutants suggests that changes in femA are contributing maximally towards P128 resistance. Since FemB protein is not expected to function in cells with inactive FemA , the mutant cells will have cross-bridges containing only a single glycine. The mutations in femA also explain the b-lactam sensitivity of the mutants, since it is known that mecA-encoded PBP 2a protein, which is refractory to b-lactams, is unable to perform transpeptidation in cells lacking pentaglycine cross-bridges (Labschinski et al. 1998; Rohrer & Berger-Bachi, 2003) . In femA mutant S. aureus cells, the transpeptidation reaction is carried out by the b-lactam-sensitive PBP 2, thus rendering the cells susceptible to b-lactams. Further proof of the link of P128 mechanism of action to the pentaglycine cross-bridge came from studies of in vitro digestion of fusion proteins containing GGGGG or its variants. The formation of monoglycine bridges in femA mutants (de Jonge et al., 1993; Stranden et al., 1997) and inability of P128 to cleave stretches with single glycine residues in vitro could explain the link between femA mutation and resistance to P128. In terms of the substrate specificities, we found that both P128 and lysostaphin act on a pentaglycine substrate and also show feeble activity on a triglycine substrate in vitro. However, one important difference seen between lysostaphin and P128 is the ability of P128 to act on a serinesubstituted pentapeptide sequence (GGSGG, AGSGG), which is present in the cell walls of certain species of staphylococci such as S. simulans biovar staphylolyticus and S. haemolyticus (Thumm & Götz, 1997; Billot-Klein et al., 1996) . Further, the in vivo relevance of the ability of P128 to cleave serine containing GGSGG or AGSGG sequence has been established by demonstration of its bactericidal activity on S. simulans biovar staphylolyticus (Saravanan et al., 2013) and S. haemolyticus. Because of this property, the spectrum of activity of P128 on Staphylococcus species is likely to be broader than that of lysostaphin.
The loss of fitness and conversion of the mutants to blactam sensitivity and the ability of P128 to inhibit certain lysostaphin-resistant variants of Staphylococcus make it an attractive candidate for clinical development.
